Authored By: Candace Whitman
The U.S. Food and Drug Administration has requested that all ranitidine drugs be removed from the market due to the contaminant N-Nitrosodimethylamine (NDMA) which is a probable carcinogen.
In September of 2019, the FDA warned the public about the potential risks of drugs containing NDMA like Zantac. They, along with other third-party laboratories, continued testing to find out more about the risks.
According to the FDA’s news release earlier this week, new testing confirms that “NDMA levels increase in ranitidine even under normal storage conditions, and NDMA has been found to increase significantly in samples stored at higher temperatures, including temperatures the product may be exposed to during distribution and handling by consumers.” They also confirmed that the levels of NDMA increase as the product ages.
With all the new evidence they have gathered, the FDA now has reason to request that all manufacturers cease sale of their product and all consumers stop taking and dispose of any ranitidine drugs they may have.
For more information, click here to read the news release from the FDA.
Photo Credit: kzenon